Wedoany.com Report on Feb 2nd, the Cell Therapy Center of the Hematology Department at Guangdong Second Provincial General Hospital in China was officially established, marking a new chapter for the hospital in the field of cell therapy.
The newly established Cell Therapy Center will build a comprehensive platform integrating medical treatment, scientific research, and translation. It will combine cell therapy with hematopoietic stem cell transplantation technology, focusing on innovative treatments for hematologic system diseases and promoting a shift in diagnosis and treatment models from traditional chemotherapy to precision immunotherapy. With a multidisciplinary collaboration model at its core, the center integrates the expertise of hematologists, transplantation specialists, immunotherapy specialists, and other professionals to provide integrated, full-cycle services for patients. Relying on optimized clinical pathways and a digital follow-up platform, it aims to achieve standardized, personalized, and sustainable treatment.
In terms of technical expertise, the hospital's Hematology Department has over a decade of experience in cell therapy research and clinical application, achieving significant results in treating diseases such as acute lymphoblastic leukemia and lymphoma. It has undertaken multiple national and provincial-level research projects in China and has been granted several invention patents. The clinical value of its innovation platform has been demonstrated in numerous real-world cases. For example, leukemia patients receiving novel CAR-T cell therapy experienced a significant decrease in the proportion of cancer cells in their bone marrow and achieved complete remission; patients with relapsed or refractory lymphoma saw the disappearance of all lesions in their bodies after intervention with innovative treatment regimens.
The center will continue to increase investment in scientific research, promote the development of new technologies such as universal CAR-T and CAR-NK, and expand indications to areas like autoimmune diseases. Through technology transfer, talent cultivation, and academic collaboration, it aims to promote the high-quality and standardized development of cell therapy, jointly build a collaborative network for cell therapy in Southern China, and benefit more patients.
